Provention Bio inks China deal for autoimmune program; Kyowa Kirin releases positive topline data in atopic dermatitis
Provention Bio is making its way into China with a new deal announced Wednesday.
The Red Bank, NJ-based biotech has agreed to a deal with a subsidiary of Huadong Medicine to work on PRV-3279, a bispecific antibody-based molecule targeting CD32B and CD79B, in China, Hong Kong, Macau and Taiwan. Provention will get $6 million upfront and up to $11.5 million in funding over the next three years to cover expected research costs.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.